Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Barchart · 10/14 15:30

Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies

Read more at globenewswire.com